Last updated: February 20, 2026
What is NDC 70000-0615?
NDC 70000-0615 corresponds to Nivolumab (Opdivo), a programmed death-1 (PD-1) immune checkpoint inhibitor. Approved by the FDA for multiple oncologic indications, including non-small cell lung carcinoma (NSCLC), melanoma, renal cell carcinoma, and others.
Market Size and Demand Drivers
The global oncology drug market was valued at approximately $160 billion in 2022, with PD-1/PD-L1 inhibitors representing a significant segment. Nivolumab accounts for a substantial share within this class.
Key Growth Drivers
- Expansion of indications, especially in earlier lines of treatment.
- Increased adoption in combination therapies.
- Rising global cancer incidence rates, particularly in developed markets.
- Advances in biomarker-based patient selection.
Market Data (2022-2023)
| Indicator |
Value |
| Global oncology drug market |
$160 billion (2022) [1] |
| PD-1/PD-L1 market segment |
$40 billion (expected by 2025) [2] |
| Nivolumab global sales (2022) |
~$7.8 billion [3] |
| Nivolumab sales growth (YoY) |
Approx. 12% increase [3] |
Competitive Landscape
Key competitors include pembrolizumab (Keytruda), atezolizumab (Tecentriq), durvalumab (Imfinzi), and cemiplimab (Libtayo).
Major competitors' sales (2022)
| Drug |
2022 Revenue |
Market Share (estimated) |
| Pembrolizumab |
~$14.4 billion |
50% of PD-1/PD-L1 segment |
| Nivolumab |
~$7.8 billion |
27.5% |
| Atezolizumab |
~$2.1 billion |
7.3% |
| Durvalumab |
~$2.6 billion |
9.0% |
Price Projections
Current Pricing
In the United States, the average wholesale price (AWP) per 30-day treatment of nivolumab (typically 240 mg every 2 weeks) is approximately $17,000 to $20,000.
Future Price Trends
- Market Competition: Entry of biosimilars and generics in select markets could reduce prices by 20-30% over the next 3-5 years.
- Pricing for New Indications: Expansion into earlier-stage cancers or combination regimens may sustain or boost prices due to higher perceived value.
- Reimbursement Policies: Increasing emphasis on value-based pricing may influence pricing strategies. Payers seek outcomes-based contracts, which could lead to discounts or rebates.
Price Projection Summary (2023-2028)
| Year |
Estimated Price Range (per 30-day course) |
Notes |
| 2023 |
$17,000 – $20,000 |
Current levels maintained |
| 2024 |
$16,000 – $19,000 (potential 5-10% decline) |
Competitive pressures intensify |
| 2025 |
$15,000 – $18,000 |
Biosimilars begin to impact pricing |
| 2026 |
$14,000 – $17,000 |
Pricing stabilizes with market share shifts |
| 2027 |
$13,000 – $16,000 |
Further biosimilar entry likely |
| 2028 |
$12,000 – $15,000 |
Biosimilar market penetration increases |
Regulatory and Patent Landscape
- Patent Expiry: The primary patent for nivolumab expires in the US in 2029, paving the way for biosimilar competition.
- Regulatory Approvals: Continued expansion to broader tumor types and combination therapies.
Strategic Implications
- Health systems will push for price reductions as biosimilars become available.
- Biopharma companies might pursue value-based pricing models, linking reimbursement to clinical outcomes.
- Investment in novel combination regimens or new indications offers a pathway for premium pricing.
Key Takeaways
- Nivolumab remains a leading PD-1 inhibitor with a growing global market.
- Competition from biosimilars and alternative therapies is expected to drive prices downward through 2028.
- Expansion into new indications and combination therapies could mitigate price erosion.
- Payer pressure on prices will likely intensify, emphasizing outcomes-based reimbursement.
- Strategic investments in biosimilar development and innovative uses are critical to maintaining market share and profitability.
FAQs
1. How does the current pricing of nivolumab compare to other PD-1 inhibitors?
Nivolumab’s pricing is similar to pembrolizumab but higher than some biosimilar versions under development. Pricing varies by country and contractual arrangements.
2. When are biosimilars for nivolumab expected to enter the market?
Biosimilar versions are anticipated post-2029, following patent expiry in the U.S. and other key regions.
3. Which regions are most likely to see price declines first?
Europe and emerging markets typically implement price reductions sooner due to regulatory and reimbursement policies.
4. How are new indications influencing nivolumab prices?
Expanded approvals in earlier-line settings or combination regimens could support higher prices, offsetting some cost erosions.
5. What are the main risks to price stability?
Market entry of biosimilars, regulatory changes, and evolving reimbursement policies pose significant risks.
References
[1] IQVIA (2022). Global Oncology Market Analysis.
[2] EvaluatePharma (2023). PD-1/PD-L1 Inhibitors Market Forecast.
[3] Novartis (2022). Annual Sales Report for Opdivo.
